Premium
THROMBOLYTIC THERAPY WITH STREPTOKINASE
Author(s) -
Chesterman C. N.,
Biggs J. C.
Publication year - 1970
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1970.tb63212.x
Subject(s) - streptokinase , fibrinolytic agent , medicine , tissue plasminogen activator , activator (genetics) , pharmacology , intensive care medicine , cardiology , myocardial infarction , receptor
An understanding of the biochemical changes brought about by the fibrinolytic activator, streptokinase, is basic to the rational use of this drug. Streptokinase has been shown to be an effective agent in the treatment of a number of thromboembolic diseases, and a predictable and safe fibrinolytic state may be monitored with a minimum of laboratory tests.